Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LakeShore Biopharma ( (LSB) ) just unveiled an update.
On March 12, 2025, LakeShore Biopharma Co., Ltd announced the adoption of an Amended 2024 Share Incentive Plan, which was approved by the board of directors. The amendment adjusts the 2024 Award Pool to 2,479,385 ordinary shares, reflecting a share consolidation effective October 1, 2024, and the early utilization of shares reserved under the original plan. This move aims to align the interests of directors, employees, and consultants with those of shareholders, potentially impacting the company’s ability to attract and retain talent.
More about LakeShore Biopharma
LakeShore Biopharma Co., Ltd operates in the biopharmaceutical industry, focusing on developing innovative therapies. The company is based in Beijing, China, and is committed to enhancing shareholder value through strategic initiatives.
YTD Price Performance: -48.75%
Average Trading Volume: 15,303
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $35.3M
See more data about LSB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue